Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Kancera AB

Kancera AB_logo
4
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Kancera AB is a biotech company focused on developing and selling drug candidates with primary indication to cure or slow the development of cancer and inflammatory diseases.

Solna, Stockholm region, Sweden

Send a message

Anglais

Kancera AB Who are we?

Kancera AB is a biotech company focused on developing and selling drug candidates with primary indication to cure or slow the development of cancer and inflammatory diseases. Cardiovascular injuries associated with myocardial infarction is an example of an inflammation that Kancera AB's drug candidates can counteract. We start with a new treatment concept and end with a patented drug candidate offered for sale to major pharmaceutical and biotech companies.

The results from the...

See more

Kancera AB is a biotech company focused on developing and selling drug candidates with primary indication to cure or slow the development of cancer and inflammatory diseases. Cardiovascular injuries associated with myocardial infarction is an example of an inflammation that Kancera AB's drug candidates can counteract. We start with a new treatment concept and end with a patented drug candidate offered for sale to major pharmaceutical and biotech companies.

The results from the recently completed Phase I clinical trial in Kancera's most developed project, the Fractalkine project, confirm that KAND567 blocks the Fractalkine system and is well tolerated in healthy subjects. Thus, the company sees a strong foundation for further development of KAND567 Phase IIa studies against inflammatory diseases and cancer.

Kancera was founded in spring 2010. The share is traded on NASDAQ OMX First North since 2011 and the number of share holders were approximately 7300 as of March 29, 2018. Kancera’s laboratories are situated in the Karolinska Institute Science Park in Stockholm, Sweden.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
771 Entities

Communities

Our history

Start in 2010

  • 2010

    Founded by experts from Karolinska Institute & pharmaceutical industry together w/ private investors

  • 2011

    Start of trading of Kancera shares on the NASDAQ OMX First North

to be continued ...